Cory Renauer
Value, research analyst, biotech, small-cap

Sarepta And Eteplirsen: Will 12 Patients Be Enough For The FDA?

Sarepta Therapeutics (NASDAQ:SRPT) creates RNA-based drugs for the treatment of serious and life threatening diseases. Its most advanced candidate is an intravenously delivered treatment for Duchenne Muscular Dystrophy [DMD]. In addition to the promising DMD program, the company also has drugs for the treatment ...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.